HIV Specialist masthead
728x90 ad placeholder

Winter 2025

Volume 17, Number 4

AI in HIV Care

Features

Featured Article

A Day in the Life of an HIV Specialist in the Agentic AI Era

What Changes and What Should Stay the Same

By By John J. Hanna, MD
The future HIV clinic is not fully automated. It is not fully virtual. And it is not fully digital. It is digitally augmented.
Integrating AI Tools in HIV Prevention and Treatment for Rural and Underserved Communities

Integrating AI Tools in HIV Prevention and Treatment for Rural and Underserved Communities

By Shameka L. Cody, PhD, AGNP-C, PMHNP-BC, FAAN; Katherine M. Dudding, PhD, RN, RNC-NIC, CNE; and Brittany C. Sanders, DNP, CRNP
Geographical disparities in HIV-related health care access and treatment adherence exist in the United States, with nearly 50 percent of new HIV infections and lower rates of pre-exposure prophylaxis (PrEP) utilization in
Teaching in the Age of Generative AI Opportunity, Risk, and a Path Forward for Health Professions Education

Teaching in the Age of Generative AI: Opportunity, Risk, and a Path Forward for Health Professions Education

By Justin Hooks, DNP, FNP-BC, AAHIVS, HIV PCP
Generative artificial intelligence (AI) is already part of how our students learn, study, and communicate. The question is no longer whether students will use it. The question is whether we, as educators,
Red and Blue States Alike Want To Limit AI in Insurance

Red and Blue States Alike Want To Limit AI in Insurance. Trump Wants To Limit the States.

By Darius Tahir and Lauren Sausser
It’s the rare policy question that unites Republican Gov. Ron DeSantis of Florida and the Democratic-led Maryland government against President Donald Trump and Gov. Gavin Newsom of California: How should health insurers

Sections

LFTD Bruce Packet
Letter from the Director

The Next Chapter of HIV Care

By Bruce J. Packett II; Executive Director, AAHIVM
From chatbots answering patient questions to the rollout of AI tools used to support patient management, the artificial intelligence (AI) era is upon us now and it’s imperative to fully understand the promise – and pitfalls – of this new technology to help guide patient care and counseling.
In the News

Fellowship to Expand HIV Prevention and PrEP Access Now In Its Third Year

The American Academy of HIV Medicine (AAHIVM) announces the third year of the Dr. Dawn K. Smith HIV Prevention Clinical Fellowship, which is funded by a grant through ViiV Healthcare.
In the News

NIH-Supported Trial Reduces HIV Incidence By 70 Percent In Rural Populations

Study used technology to extend reach of existing infrastructure, linking people to care.

By The National Institute of Allergy and Infectious Diseases (NIAID)
A study funded by the National Institutes of Health (NIH) reduced new HIV cases by 70 percent in rural Kenya and Uganda by pairing digital tools with tailored HIV services delivered by community health workers and clinicians.
In the News

ViiV Healthcare Reports Long-Acing Injectable Cabenuva Effectively Maintains Viral Suppression in Adolescents Living with HIV, with >97 Percent Preferring Injections Over Daily Oral Treatment

ViiV Healthcare announced week 96 and end-of-study results from the phase I/II IMPAACT 2017 (MOCHA) study, the first trial to evaluate a complete injectable long-acting treatment regimen in adolescents living with HIV.
In the News

New Data Show Over 91 Percent Viral Suppression Rate Among Ryan White HIV/AIDS Program Patients

The Health Resources and Services Administration (HRSA) released new data, marking a record-breaking 91.4 percent of patients receiving HIV medical care through the Ryan White HIV/AIDS Program were virally suppressed, significantly exceeding the national viral suppression rate.
300x250 ad placeholder
At the Forefront

Maintenance of Viral Suppression with Long-Acting Cabotegravir and Rilpivirine During Pregnancy: A Case Report

By Blair Thedinger, MD, AAHIVS, and Aaron Sriram Devanathan, PharmD, PhD, AAHIVP
Long-acting injectable antiretroviral therapy (LA-ART) using cabotegravir and rilpivirine is an emerging strategy to address adherence challenges among people with HIV.
Clinical Research Update

Clinical Research Update – Winter 2025

By Carolyn Chu, MD, MSC, AAHIVS; AAHIVM Chief Medical Officer
728x90 ad placeholder
Scroll to Top

Search